Levi & Korsinsky has launched an investigation into Pharming Group concerning potential securities law violations. The investigation follows a 22% drop in Pharming Group stock on July 30, 2026, after the company reported second-quarter revenue of $90.2 million, down 3% year-over-year, and cut its full-year 2026 revenue guidance to $375-$395 million from $405-$425 million. The revenue shortfall was primarily driven by a 10% decline in sales of its legacy hereditary angioedema therapy RUCONEST to $72.3 million, while Joenja revenue rose 40% to $17.9 million. The firm is examining whether Pharming Group and certain officers failed to adequately disclose competitive and demand pressures affecting RUCONEST prior to the announcement. Investors who suffered losses are encouraged to contact the firm for a free case evaluation.
Pharming Group NVQ2 revenue miss and guidance cut trigger securities investigation
